Form 4: Pfizer R&D President Sells Shares for Tax Obligations

Pfizer's President of R&D, Christoffel Boshoff, reported a routine disposition of 12,887 shares to cover tax liabilities from restricted stock unit vesting.

Summary

• Christoffel Boshoff, President, R&D of Pfizer Inc. (PFE), reported a transaction involving the disposition of common stock.
• On January 30, 2026, Boshoff disposed of 12,887 shares of Pfizer common stock at a price of $26.44 per share.
• This transaction was executed to satisfy tax obligations upon the vesting of restricted stock units, including dividend equivalents.
• Following this transaction, Boshoff directly beneficially owns 155,645 shares of common stock.
• Additionally, Boshoff indirectly beneficially owns 698 shares of common stock through a Rule 16b-3 Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative transaction for tax purposes related to executive compensation, rather than a discretionary sale or a reflection of company performance.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as the disposition of shares for tax withholding upon RSU vesting, are common across all industries, particularly in large, established pharmaceutical companies like Pfizer. These transactions are typically administrative and do not reflect a change in management's outlook or the company's operational performance.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in company fundamentals or management's confidence.

Key Dates

Keywords

Pfizer, PFE, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Executive Compensation